MabThera/Rituxan

Roche’s MabThera ends drug drought for serious skin disease

Roche’s ageing blockbuster MabThera has picked up a new approval in life-threatening skin disorder pemphigus vulgaris, becoming the first new treatment for the disease in six decades. ... MabThera (rituximab) – an anti-CD20 antibody known as Rituxan

Ocrevus helps Roche stave off biosimilar threat

The third of the big three - Mabthera/Rituxan (rituximab) - did not fare as well as its peers however, with sales down 8% to CHF 1.7bn overall and plummeting 44% in

Morning brief: Roche raises outlook for 2018, ASCO abstracts revealed and more

from blockbusters Avastin, Herceptin and Mabthera/Rituxan.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

MSD launches EU’s first biosimilar Herceptin in UK

Roche has particularly high exposure to biosimilar erosion in the coming years in its first-generation antibody products - with Avastin (bevacizumab) and MabThera (rituximab) also under threat along with Herceptin - but

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]